Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Hilton Pharma (Pvt) Limited.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000136 262 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx262product presentations
G61generic molecules
DF9dosage-form groups
TA11therapeutic areas
PKR262current price records
REG175registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixHilton Pharma (Pvt) Limited.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026Anti-infectives100 · 38%CNS & mental health75 · 29%Endocrine & metabolic23 · 9%Cardiovascular16 · 6%Hematology & thrombosis16 · 6%Oncology & immunology10 · 4%Gastrointestinal & hepatology10 · 4%Other therapeutic areas12 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioHilton Pharma (Pvt) Limited.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026262presentationsTablet190 · 73%Capsule21 · 8%Injection20 · 8%Suspension12 · 5%Solution6 · 2%Syrup6 · 2%Other forms7 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionHilton Pharma (Pvt) Limited.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026240comparable productsBelow market median32 · 13%Near market median92 · 38%Above market median116 · 48%Company median price position+4.7%Lowest-price equivalents25Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsHilton Pharma (Pvt) Limited.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,39 shared64% overlapM/s. Genix Pharma (Pvt) Ltd.39 shared64% overlapCCL Pharmaceuticals (Pvt.) Ltd.37 shared61% overlapGenome Pharmaceuticals (Pvt.) Ltd,36 shared59% overlapHigh-Q Pharmaceuticals34 shared56% overlapGetz Pharma (Pvt) Limited32 shared52% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives100 products · 38%
CNS & mental health75 products · 29%
Endocrine & metabolic23 products · 9%
Cardiovascular16 products · 6%
Hematology & thrombosis16 products · 6%
Oncology & immunology10 products · 4%
Gastrointestinal & hepatology10 products · 4%
Vitamins, minerals & nutrition7 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antiepileptics31 products · 12%
Antivirals30 products · 11%
Antidiabetic medicines23 products · 9%
Antipsychotics23 products · 9%
Antimalarials21 products · 8%
Macrolide antibacterials12 products · 5%
Anticoagulants12 products · 5%
Calcium-channel blockers11 products · 4%
Formulation footprint

Dosage forms

Tablet190 products
Capsule21 products
Injection20 products
Suspension12 products
Solution6 products
Syrup6 products
Infusion4 products
Other2 products
Drops1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 LERACELevetiracetam 24presentations 100 mg/mL, 1000 mg, 250 mg, 500 mg · Solution, Tablet, Injection #2 REZCALMRisperidone 13presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #3 NOVIARibavirin 10presentations 200 mg, 400 mg, 500 mg, 600 mg · Tablet #4 RIVARRivaroxaban 10presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #5 XENGLUEmpagliflozin 10presentations 10 mg, 25 mg · Tablet #6 HifloxCiprofloxacin 8presentations 100 mg, 100 MG, 125 mg/5 mL, 200 mg/100 mL · Tablet, Infusion, Suspension
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3213% of comparable products
Near market median92within ±5% of median
Above market median11648% of comparable products
Lowest-price equivalents25ties included
Company median price position +4.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
CEFIM 400 mgCefixime · Tablet · 1x5's PKR 65.00/tablet-47.1% vs market median HILPEP 300 mgRanitidine · Tablet · 1X10's PKR 16.45/tablet-22.7% vs market median HILOMET XR 1000 mgMetformin · Tablet · 5x10's PKR 3.11/tablet-19.8% vs market median HILZIDE 80 mgGliclazide · Tablet · 2 × 10's PKR 8.85/tablet-16.9% vs market median XENGLU 25 mgEmpagliflozin · Tablet · 28's PKR 83.79/tablet-16.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 39shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 39shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 37shared generics Genome Pharmaceuticals (Pvt.) Ltd,149 products · 71 generics 36shared generics High-Q Pharmaceuticals196 products · 59 generics 34shared generics Getz Pharma (Pvt) Limited289 products · 64 generics 32shared generics
Regulatory & price activity

Observed database signals

Registration numbers175
Price-history records342
Products with price history45
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

31 results
Intelligence filter: Drug classAntiepileptics Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
LERACE Levetiracetam 750 mg Tablet 30'S 053350 PKR 4,216.10 PKR 140.54/tablet 7% above median
LERACE Levetiracetam 750 mg Tablet 30's 107780 PKR 3,667.49 PKR 122.25/tablet 7% below median
LERACE Levetiracetam 750 mg Tablet 20's 053350 PKR 3,118.61 PKR 155.93/tablet 19% above median
LERACE Levetiracetam 750 mg Tablet 10'S 053350 PKR 1,707.92 PKR 170.79/tablet 30% above median
LERACE Levetiracetam 750 mg Tablet 10's 107780 PKR 1,273.55 PKR 127.36/tablet Near median
LERACE Levetiracetam 500 mg Tablet 20's 070417 PKR 2,268.91 PKR 113.45/tablet 21% above median
LERACE Levetiracetam 250 mg Tablet 10'S 053348 PKR 790.04 PKR 79.00/tablet 43% above median
LERACE Levetiracetam 100 mg/mL Oral solution 30ml 061224 PKR 488.72 PKR 16.29/mL 22% above median
LERACE Levetiracetam 250 mg Tablet 20's 053348 PKR 1,443.02 PKR 72.15/tablet 31% above median
LERACE Levetiracetam 1000 mg Tablet 30's 053351 PKR 4,103.66 PKR 136.79/tablet 10% below median
LERACE Levetiracetam 500 mg Tablet 10's 070417 PKR 1,242.60 PKR 124.26/tablet 32% above median
LERACE Levetiracetam 500 mg Tablet 20's 053349 PKR 2,393.43 PKR 119.67/tablet 27% above median
LERACE Levetiracetam 100 mg/mL Oral solution 60ml 061224 PKR 887.72 PKR 14.80/mL 11% above median
LERACE Levetiracetam 500 mg/5 mL Injection 1's 066949 PKR 733.08 PKR 733.08/vial/unit 19% above median
LERACE Levetiracetam 500 mg Tablet 30'S 053349 PKR 3,163.68 PKR 105.46/tablet 12% above median
LERACE Levetiracetam 500 mg/5 mL Injection 10's 066949 PKR 6,047.15 PKR 604.72/vial/unit Near median
LERACE Levetiracetam 500 mg Tablet 10'S 053349 PKR 1,311.09 PKR 131.11/tablet 39% above median
LERACE Levetiracetam 100 mg/mL Oral solution 10ml 061224 PKR 145.46 PKR 14.55/mL 9% above median
LERACE Levetiracetam 500 mg Extended-release tablet 14's 070417 PKR 1,739.64 PKR 124.26/tablet 11% above median
LERACE Levetiracetam 1000 mg Tablet 10's 053351 PKR 2,024.49 PKR 202.45/tablet 33% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.